Literature DB >> 36204167

A Cannabinoid Hypothesis of Schizophrenia: Pathways to Psychosis.

Rachel Little1, Dale D'Mello2.   

Abstract

Background: Observations regarding psychostimulant and psychedelic drug-induced psychotic states led to the dopamine, serotonin, and glutamate hypotheses of schizophrenia. Expanding knowledge about the endocannabinoid system and the impact of exogenous cannabinoids on the brain and behavior have elucidated several putative pathways to cannabis-induced psychosis. Objective: The purpose of the present article was to describe these pathways and propose a cannabinoid hypothesis of schizophrenia. Main points: The endocannabinoid system was reviewed. Evidence regarding the effect of delta 9-tetrahydrocannabinol (THC) on the brain was described. A connection between cannabis use and first-episode psychosis was elucidated.
Conclusion: Understanding the putative pathways to cannabis-induced psychosis might lead to targeted therapeutic interventions and prevention of schizophrenia in susceptible individuals.
Copyright © 2022. Matrix Medical Communications. All rights reserved.

Entities:  

Keywords:  CBD; Cannabis; THC; mainstream; psychosis; schizophrenia

Year:  2022        PMID: 36204167      PMCID: PMC9507146     

Source DB:  PubMed          Journal:  Innov Clin Neurosci        ISSN: 2158-8333


  49 in total

Review 1.  Review of the validity and significance of cannabis withdrawal syndrome.

Authors:  Alan J Budney; John R Hughes; Brent A Moore; Ryan Vandrey
Journal:  Am J Psychiatry       Date:  2004-11       Impact factor: 18.112

2.  Reasons for cannabis use: patients with schizophrenia versus matched healthy controls.

Authors:  Michael Schaub; Kyra Fanghaenel; Rudolf Stohler
Journal:  Aust N Z J Psychiatry       Date:  2008-12       Impact factor: 5.744

3.  Cannabis use in young people: the risk for schizophrenia.

Authors:  Paola Casadio; Cathy Fernandes; Robin M Murray; Marta Di Forti
Journal:  Neurosci Biobehav Rev       Date:  2011-04-16       Impact factor: 8.989

4.  Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting.

Authors:  Mary Barna Bridgeman; Daniel T Abazia
Journal:  P T       Date:  2017-03

Review 5.  The hippocampal formation in schizophrenia.

Authors:  Carol A Tamminga; Ana D Stan; Anthony D Wagner
Journal:  Am J Psychiatry       Date:  2010-09-01       Impact factor: 18.112

Review 6.  Interventions for cannabis use disorder.

Authors:  Ken C Winters; Joel Mader; Alan J Budney; Catherine Stanger; Ashley A Knapp; Denise D Walker
Journal:  Curr Opin Psychol       Date:  2020-11-17

7.  Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory analysis of the PRIDE study.

Authors:  H Lynn Starr; Jason Bermak; Lian Mao; Steve Rodriguez; Larry Alphs
Journal:  Schizophr Res       Date:  2017-06-07       Impact factor: 4.939

8.  Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases.

Authors:  Mikkel Arendt; Raben Rosenberg; Leslie Foldager; Gurli Perto; Povl Munk-Jørgensen
Journal:  Br J Psychiatry       Date:  2005-12       Impact factor: 9.319

Review 9.  Medicinal Cannabis-Potential Drug Interactions.

Authors:  Muhammad A Alsherbiny; Chun Guang Li
Journal:  Medicines (Basel)       Date:  2018-12-23

10.  Association of Cannabis Use During Adolescence With Neurodevelopment.

Authors:  Matthew D Albaugh; Jonatan Ottino-Gonzalez; Amanda Sidwell; Claude Lepage; Anthony Juliano; Max M Owens; Bader Chaarani; Philip Spechler; Nicholas Fontaine; Pierre Rioux; Lindsay Lewis; Seun Jeon; Alan Evans; Deepak D'Souza; Rajiv Radhakrishnan; Tobias Banaschewski; Arun L W Bokde; Erin Burke Quinlan; Patricia Conrod; Sylvane Desrivières; Herta Flor; Antoine Grigis; Penny Gowland; Andreas Heinz; Bernd Ittermann; Jean-Luc Martinot; Marie-Laure Paillère Martinot; Frauke Nees; Dimitri Papadopoulos Orfanos; Tomáš Paus; Luise Poustka; Sabina Millenet; Juliane H Fröhner; Michael N Smolka; Henrik Walter; Robert Whelan; Gunter Schumann; Alexandra Potter; Hugh Garavan
Journal:  JAMA Psychiatry       Date:  2021-06-16       Impact factor: 25.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.